Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Nick Goulden"'
Autor:
Jack Bartram, Nick Goulden, Gary Wright, Stuart Adams, Tony Brooks, Darren Edwards, Sarah Inglott, Yasar Yousafzai, Mike Hubank, Christina Halsey
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Externí odkaz:
https://doaj.org/article/df52f9e744354f35979c3b15b766a240
Autor:
Julie Irving, Jenny Jesson, Paul Virgo, Marian Case, Lynne Minto, Lisa Eyre, Nigel Noel, Ulrika Johansson, Marion Macey, Linda Knotts, Margaret Helliwell, Paul Davies, Liam Whitby, David Barnett, Jeremy Hancock, Nick Goulden, Sarah Lawson
Publikováno v:
Haematologica, Vol 94, Iss 6 (2009)
Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes
Externí odkaz:
https://doaj.org/article/addd4a6fb56a4df8b98a9a2c05de8ed8
Autor:
Jack Bartram, Gary Wright, Stuart Adams, Paul Archer, Tony Brooks, Darren Edwards, Jerry Hancock, Henrik Knecht, Sarah Inglott, Edward Mountjoy, Marie Roynane, Stephanie Wakeman, John Moppett, Mike Hubank, Nick Goulden
Publikováno v:
Pediatric bloodcancerREFERENCES. 69(3)
Minimal residual disease (MRD) measured on end-of-induction bone marrow (BM) is the most important biomarker for guiding therapy in pediatric acute lymphoblastic leukemia (ALL). Due to limited sensitivity of current approaches, peripheral blood (PB)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fc41b8364f96935f66b4dcde1a41731
https://pubmed.ncbi.nlm.nih.gov/34971078
https://pubmed.ncbi.nlm.nih.gov/34971078
Autor:
Simone Stokley, Donna Lancaster, Neha Bhatnagar, Deborah Richardson, Christine J. Harrison, Sujith Samarasinghe, Frederik W. van Delft, John Moppett, Katharine Patrick, Alice Norton, Claire Schwab, Brenda Gibson, Emily Winterman, Anna Castleton, Pamela Kearns, Beki James, Andrew McMillan, Mabrouk S. Madi, Michelle Cummins, Jayashree Motwani, Anthony V. Moorman, Aengus O'Marcaigh, Amrana Qureshi, Ajay Vora, Amy A Kirkwood, Gordon Taylor, Jerry Hancock, Nick Goulden
Publikováno v:
British journal of haematologyReferences. 191(5)
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562d40c1fb856c32d9bd784f28ef93e4
https://pubmed.ncbi.nlm.nih.gov/32926422
https://pubmed.ncbi.nlm.nih.gov/32926422
Autor:
Nick Goulden, Mike Hubank, Katerina A. Nicolaou, George S. Vassiliou, L Loizou, Jianxiang Chi, Laura Koumas, Paul Costeas, Jack Bartram, Rachael Bashford-Rogers, Paul Kellam
Publikováno v:
Leukemia
The strongest predictor of relapse in B-cell acute lymphoblastic leukemia (B-ALL) is the level of persistence of tumor cells after initial therapy. The high mutation rate of the B-cell receptor (BCR) locus allows high-resolution tracking of the archi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54d9d7b34a8101af9a38faeca0767ec
https://doi.org/10.1038/leu.2016.142
https://doi.org/10.1038/leu.2016.142
Autor:
Georg Hempel, Julie Errington, Gareth J. Veal, John Moppett, Pamela Kearns, Jizhong Liu, Sujith Samarasinghe, Nick Goulden, Philip Berry, Vaskar Saha, Ajay Vora, Rachael Hough, Catriona Parker, Rosanna K. Jackson, Martina Liebich, Julie Irving, Clare Rowntree
Publikováno v:
European journal of cancer (Oxford, England : 1990). 120
Introduction The use of dexamethasone in acute lymphoblastic leukaemia therapy contributes to short- and long-term toxicities. The UKALL 2011 randomised trial investigated whether a more intense dexamethasone dose (10 mg/m2/d x 14d, short vs 6 mg/m2/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7122c0bc5152bd18195f7eff83f08aee
https://pubmed.ncbi.nlm.nih.gov/31499383
https://pubmed.ncbi.nlm.nih.gov/31499383
Autor:
Jack Bartram, Mike Hubank, John Moppett, Gary Wright, Jeremy Hancock, Helen Williamson, Nick Goulden, Edward Mountjoy, Tony Brooks
Publikováno v:
The Journal of Molecular Diagnostics. 18:494-506
High-throughput sequencing (HTS) (next-generation sequencing) of the rearranged Ig and T-cell receptor genes promises to be less expensive and more sensitive than current methods of monitoring minimal residual disease (MRD) in patients with acute lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec77ca109828e048e9c7a5e8f95c6305
https://doi.org/10.1016/j.jmoldx.2016.02.008
https://doi.org/10.1016/j.jmoldx.2016.02.008
Autor:
Stuart Adams, Sarah Inglott, Gary Wright, Nick Goulden, Tony Brooks, Darren Edwards, Jack Bartram, Mike Hubank, Christina Halsey, Yasar Mehmood Yousafzai
Optimal management of central nervous system (CNS) infiltration is a key remaining challenge in delivering precision therapy for childhood acute lymphoblastic leukemia (ALL).[1][1] Most CNS relapses occur in children without high-risk features, and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00eec203234c497e0f6316115558e943
https://eprints.gla.ac.uk/152615/1/152615.pdf
https://eprints.gla.ac.uk/152615/1/152615.pdf
Autor:
M M van den Heuvel-Eibrink, Mike Hubank, Sujith Samarasinghe, Jack Bartram, Darren J. Edwards, Christian M. Zwaan, A Khwaja, Tony Brooks, P Ancliff, J de Boer, Nick Goulden, Owen Williams, Gareth Williams, Walf-Vorderwulbecke, K. Pearce, Stuart Adams
Publikováno v:
Leukemia, 32(4), 882-889. Nature Publishing Group
Despite advances in our understanding of the molecular basis for particular subtypes of acute myeloid leukemia (AML), effective therapy remains a challenge for many individuals suffering from this disease. A significant proportion of both pediatric a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58aeb03ae38e157bf16b8b09d9a7e68b
https://pure.eur.nl/en/publications/99b3892b-08eb-448e-aae3-8da06d62ae36
https://pure.eur.nl/en/publications/99b3892b-08eb-448e-aae3-8da06d62ae36
Autor:
David, O'Connor, Amir, Enshaei, Jack, Bartram, Jeremy, Hancock, Christine J, Harrison, Rachael, Hough, Sujith, Samarasinghe, Claire, Schwab, Ajay, Vora, Rachel, Wade, John, Moppett, Anthony V, Moorman, Nick, Goulden
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(1)
Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize MRD data and do not assimilate genetics when assigning MRD risk, which reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3f9c18c326f5c0010b408d2fb3460e1
https://pubmed.ncbi.nlm.nih.gov/29131700
https://pubmed.ncbi.nlm.nih.gov/29131700